Page 77 - 51 the significance--29.2_opt

59. Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q, Alogliptin Study G. Efficacy and
safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in
patients with type 2 diabetes: a randomized, double-blind, placebo-controlled
study. Current medical research and opinion 2009;25(10):2361-71.
60. Kaku K, Itayasu T, Hiroi S, Hirayama M, Seino Y. Efficacy and safety of alogliptin added
to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-
blind, placebo-controlled trial with an open-label long-term extension study. Diabetes,
obesity & metabolism 2011;13(11):1028-35.
61. Rosenstock J, Inzucchi SE, Seufert J, Fleck PR, Wilson CA, Mekki Q. Initial combination
therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes.
Diabetes care 2010;33(11):2406-8.
62. Bosi E, Ellis GC, Wilson CA, Fleck PR. Alogliptin as a third oral antidiabetic drug in
patients with type 2 diabetes and inadequate glycaemic control on metformin
and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-
group study. Diabetes, obesity & metabolism 2011;13(12):1088-96.
63. Frederich R, Alexander JH, Fiedorek FT, Donovan M, Berglind N, Harris S, et al. A
systematic assessment of cardiovascular outcomes in the saxagliptin drug develop-
ment program for type 2 diabetes. Postgrad Med;122(3):16-27.
64. Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptydil peptidase-4 inhibitors
in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc
Dis;20(4):224-35.
65. Williams-Herman D, Engel SS, Round E, Johnson J, Golm GT, Guo H, et al. Safety and
tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246
patients with type 2 diabetes. BMC Endocr Disord;10:7.
66. Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W. Assessing
the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated
events from a large Phase III type 2 diabetes population. Diabetes, obesity & meta-
bolism;12(6):485-94.
67. Kahn SE. The relative contribution of insulin resistance and beta-cell dysfunction to
the pathophysiology of type 2 diabetes. Diabetologia 2003;46:3-19.
68. Marchetti P, Dotta F, Lauro D, Purrello F. An overview of pancreatic beta-cell defects
in human type 2 diabetes: implications for treatment. Regul Pept 2008;146(1-3):4-11.
69. Donath MY, Storling J, Maedler K, Mandrup-Poulsen T. Inflammatory mediators
and islet beta-cell failure: a link between type 1 and type 2 diabetes. J Mol Med
2003;81(8):455-70.
70. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and
increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52(1):
102-10.
71. Drews G, Krippeit-Drews P, Dufer M. Oxidative stress and beta-cell dysfunction.
Pflugers Arch 2010;460(4):703-18.
72. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation
of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacologi-
cal treatment of insulin resistance in high-risk hispanic women. Diabetes 2002;51(9):
2796-803.
73. Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, et al. Role of
insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes
prevention program: effects of lifestyle intervention and metformin. Diabetes 2005;
54(8):2404-14.
74. Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, et al. Dipeptidyl peptidase IV
inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-
induced diabetic rats. Diabetes 2003;52(3):741-50.
75. Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, et al. Chronic inhibition of dipeptidyl
peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and
function in a rodent model of type 2 diabetes. Diabetes 2006;55(6):1695-704.
76. Marchetti P, Lupi R, Del Guerra S, Bugliani M, D’Aleo V, Occhipinti M, et al. Goals
of treatment for type 2 diabetes: beta-cell preservation for glycemic control.
Diabetes care 2009;32 Suppl 2:S178-83.
77. Ahren B. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes.
Expert opinion on emerging drugs 2008;13(4):593-607.
78. Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH. The role of CD26/
dipeptidyl peptidase IV in cancer. Front Biosci 2008;13:1634-45.
79. Masur K, Schwartz F, Entschladen F, Niggemann B, Zaenker KS. DPPIV inhibitors extend
GLP-2 mediated tumour promoting effects on intestinal cancer cells. Regul Pept
2006;137(3):147-55.

77